Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia
RecruitingNot applicableNCT07123987
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN). Participants will receive taVNS in addition to standard care. The study aims to determine whether taVNS can provide significant pain relief and improve quality of life in PHN patients.
Study details
- Official title
- Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia
- Conditions
- Post Herpetic Neuralgia (PHN)
- Interventions
- Device: transcutaneous auricular vagus nerve stimulation (taVNS)
- Other: traditional medical treatment for PHN
- Sponsor
- Mohamed Hosny Ismail Easa
- Organization
- Cairo University
- Start date
- 2025-09-07
- Primary completion
- 2026-09-09
- Sex
- All
- Age range
- from 35 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: Adults aged 35-65 years diagnosed with PHN. Persistent pain for at least 3 months after herpes zoster infection. Only patients who sign the informed consent form will be included. Exclusion Criteria: Contraindications to taVNS such as: 1. pregnancy; 2. active implants (e.g., pacemakers, cochlear implants) or brain shunts; 3. previous neurological or psychiatric diagnoses; 4. history of addiction or substance abuse; 5. history of trauma and/or brain surgery; 6. cardiac disease; 7. acute or chronic use of medications and/or illicit drugs; 8. susceptibility to headaches and seizures. Severe cognitive impairment. Other chronic pain conditions.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07123987